The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

被引：1266
|
作者：
Caly, Leon [1 ]
Druce, Julian D. [1 ]
Catton, Mike G. [1 ]
Jans, David A. [2 ]
Wagstaff, Kylie M. [2 ]
机构：
[1] Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Reference Lab, Melbourne, Vic 3000, Australia
[2] Monash Univ, Biomed Discovery Inst, Clayton, Vic 3800, Australia
来源：
ANTIVIRAL RESEARCH | 2020年 / 178卷
基金：
英国医学研究理事会;
关键词：
NUCLEAR IMPORT; NUCLEOCAPSID PROTEIN; LOCALIZATION; VIRUSES; TRANSPORT; SAFETY;
D O I：
10.1016/j.antiviral.2020.104787
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect -5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine
    Plaze, Marion
    Attali, David
    Prot, Matthieu
    Petit, Anne-Cecile
    Blatzer, Michael
    Vinckier, Fabien
    Levillayer, Laurine
    Chiaravalli, Jeanne
    Perin-Dureau, Florent
    Cachia, Arnaud
    Friedlander, Gerard
    Chretien, Fabrice
    Simon-Loriere, Etienne
    Gaillard, Raphael
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (03)
  • [2] The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells
    Rothan, Hussin A.
    Stone, Shannon
    Natekar, Janhavi
    Kumari, Pratima
    Arora, Komal
    Kumar, Mukesh
    [J]. VIROLOGY, 2020, 547 : 7 - 11
  • [3] Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro
    Xiong, Hua-Long
    Cao, Jia-Li
    Shen, Chen-Guang
    Ma, Jian
    Qiao, Xiao-Yang
    Shi, Tian-Shu
    Ge, Sheng-Xiang
    Ye, Hui-Ming
    Zhang, Jun
    Yuan, Quan
    Zhang, Tian-Ying
    Xia, Ning-Shao
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [4] Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
    Jeon, Sangeun
    Ko, Meehyun
    Lee, Jihye
    Choi, Inhee
    Byun, Soo Young
    Park, Soonju
    Shum, David
    Kim, Seungtaek
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [5] The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters
    Shytaj, Iart Luca
    Fares, Mohamed
    Gallucci, Lara
    Lucic, Bojana
    Tolba, Mahmoud M.
    Zimmermann, Liv
    Adler, Julia M.
    Xing, Na
    Bushe, Judith
    Gruber, Achim D.
    Ambiel, Ina
    Ayoub, Ahmed Taha
    Cortese, Mirko
    Neufeldt, Christopher J.
    Stolp, Bettina
    Sobhy, Mohamed Hossam
    Fathy, Moustafa
    Zhao, Min
    Laketa, Vibor
    Diaz, Ricardo Sobhie
    Sutton, Richard E.
    Chlanda, Petr
    Boulant, Steeve
    Bartenschlager, Ralf
    Stanifer, Megan L.
    Fackler, Oliver T.
    Trimpert, Jakob
    Savarino, Andrea
    Lusic, Marina
    [J]. MBIO, 2022, 13 (02):
  • [6] Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
    Joel, C.
    Jebakumar, D. S. Ivan
    Bennie, R. Biju
    Ebenezer, Cheriyan
    Solomon, Rajadurai Vijay
    Abraham, S. Daniel
    [J]. IRANIAN JOURNAL OF SCIENCE, 2023, 47 (03) : 617 - 630
  • [7] Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
    Taha, Zaid
    Arulanandam, Rozanne
    Maznyi, Glib
    Godbout, Elena
    Carter-Timofte, Madalina E.
    Kurmasheva, Naziia
    Reinert, Line S.
    Chen, Andrew
    Crupi, Mathieu J. F.
    Boulton, Stephen
    Laroche, Genevieve
    Phan, Alexandra
    Rezaei, Reza
    Alluqmani, Nouf
    Jirovec, Anna
    Acal, Alexandra
    Fekete, Emily E. F.
    Singaravelu, Ragunath
    Petryk, Julia
    Idorn, Manja
    Potts, Kyle G.
    Todesco, Hayley
    John, Cini
    Mahoney, Douglas J.
    Ilkow, Carolina S.
    Giguere, Patrick
    Alain, Tommy
    Cote, Marceline
    Paludan, Soren R.
    Olagnier, David
    Bell, John C.
    Azad, Taha
    Diallo, Jean-Simon
    [J]. MOLECULAR THERAPY, 2022, 30 (09) : 2998 - 3016
  • [8] Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
    C. Joel
    D. S. Ivan Jebakumar
    R. Biju Bennie
    Cheriyan Ebenezer
    Rajadurai Vijay Solomon
    S. Daniel Abraham
    [J]. Iranian Journal of Science, 2023, 47 : 617 - 630
  • [9] Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication
    Pirzada, Rameez Hassan
    Haseeb, Muhammad
    Batool, Maria
    Kim, MoonSuk
    Choi, Sangdun
    [J]. CELLS, 2021, 10 (05)
  • [10] Losartan Inhibits SARS-CoV-2 Replication in vitro
    Nejat, Reza
    Sadr, Ahmad Shahir
    Freitas, Brendan T.
    Murray, Jackelyn
    Pegan, Scott D.
    Tripp, Ralph A.
    Najafi, David J.
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2021, 24 : 390 - 399
12345